Fibroblast growth factor 23: friend or foe in uremia?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22728930.
- Also identified by DOI 10.1172/JCI64184 and PMC identifier 3386835.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Uremia is a complex metabolic state marked by derangement of many signaling molecules and metabolic intermediates; of these, the massively increased levels of FGF23 are among the most striking. It has remained unclear whether FGF23 is directly implicated in the pathogenesis of chronic kidney disease (CKD) and its complications, a consequence of other dysregulated pathways, or perhaps an adaptive - and thus desirable - response. In this issue of the JCI, Shalhoub et al. describe the chronic effects of antibody-mediated FGF23 neutralization in a CKD mouse model, shedding new light on this complicated story and moving us one step closer to understanding the role of FGF23 in CKD.
Medical subject headings
- Fibroblast Growth Factors
- Hyperparathyroidism, Secondary
- Renal Insufficiency, Chronic